Articles Related to chemotherapy
Safety Concerns of Glaucoma Chemotherapy among G6PD Deficient Glaucoma Patients: A Pilot Study
The aim of this study was to assess the potential acute adverse effects associated with the use of anti-glaucoma medications
among glaucoma patients with Glucose-6-Phosphate Dehydrogenase deficiency.
Complete Clinical Response after Induction Chemotherapy Followed by Chemoradiotherapy in Nasopharyngeal Carcinoma: Impact on Oncologic Outcomes
Objective: Concomitant chemoradiation (RCT) represents the standard of care for locally-advanced nasopharyngeal carcinoma (NPC).Nevertheless induction chemotherapy (IC) followed by RCT is currently an attractive approach. Some trials showed a survival benefit of this therapeutic strategy. The aim of this study was to analyze complete clinical response (CCR) after IC and to assess its impact on disease control and survival.
The Use of Cardiac Resynchronization Therapy in Cancer Patients with Heart Failure
Investigate the use of cardiac resynchronization therapy (CRT) in cancer patients with heart failure (HF); assess factors associated with ischemic and non-ischemic HF.
Many newer cancer therapies are cardiotoxic; thus, the incidence of HF has been increasing in this high-risk patient population. CRT has beneficial effects on morbidity, mortality, and left ventricular function in patients with non-ischemic cardiomyopathy, yet cancer patients and survivors who develop severe HF and are eligible for CRT often does not receive it.
Evaluating the Effect of Oprelvekin on Cardiac Repolarization in Subjects with Chemotherapy-Induced Thrombocytopenia: An Observational Chart Review of a Phase 2 Clinical Trial in Laredo, Texas
This study tested for the cardiac effects of Oprelvekin, recombinant human interleukin-11, a thrombopoietic growth factor, in patients afflicted with chemotherapy-induced thrombocytopenia (platelet count<50,000 cells/ul). Chart-reviews of patients fulfilling the inclusion criteria of: 18-75 yrs of age, non-myeloid malignancy, with adequate hematologic, hepatic and renal parameters and normal electrocardiograms that were enrolled in this phase 2 trial were analyzed. Patients of child-bearing potential agreed to be on a reliable form of birth control for the duration of the study. Results on 4 patients suggest that Oprelvekin does not cause atrial nor ventricular arrhythmia, a rare severe cardiac side effect, in treating patients with chemotherapy-induced thrombocytopenia.
Overuse and Misuse of Adjuvant Chemotherapy for Stages I and II Non-Small Cell Lung Cancer Chemotherapy: Empirical Findings from a Privately Insured Population
Among persons with early stage non-small cell lung cancer (NSCLC) resected for cure, appropriate use of adjuvant chemotherapy is an important additional determinant of survival. Oncology quality improvement initiatives focus on reducing overuse, underuse, and misuse.
Editorial Board Members Related to chemotherapy
PATRICIA A. KRUK
Professor
Department of Obstetrics and Gynecology
USF Morsani College of Medicine
University of South Florida
United States
Department of Obstetrics and Gynecology
USF Morsani College of Medicine
University of South Florida
United States
Shi J. Liu
Professor
Department of Pharmaceutical Sciences
University of Arkansas for Medical Sciences
United States
Department of Pharmaceutical Sciences
University of Arkansas for Medical Sciences
United States
Lili Chen
Associate Professor
Department of Radiation Oncology
Fox Chase Cancer Center
United States
Department of Radiation Oncology
Fox Chase Cancer Center
United States